Skip to Main Content

Paper Details

Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
J Control Release
35
2016
Author NameAffiliation
Webster K CaveneeLudwig Institute for Cancer Research, University of California
Frank B FurnariLudwig Institute for Cancer Research, University of California
  • 1 - 2

Datasets

Release 1.2